Yes, methylation biomarkers have applications beyond cancer. In cardiovascular diseases, the methylation status of the FOXP3 gene can be indicative of atherosclerosis. In neurological disorders, changes in the methylation patterns of the APOE gene are associated with Alzheimer's disease. These biomarkers offer potential for early diagnosis and monitoring of disease progression in various non-cancer conditions.
